Table 2. Summary table: base, inclusion data.
| Groups | Microcirculation model | Edema score | Symptoms | Oxidative stress | 10 Paresthesia (number) | Score 0–5 | ||
|---|---|---|---|---|---|---|---|---|
| R-FLUX | PO 2 | PCO 2 | Score 0–5 | |||||
| 1. VENOR | 2.82 | 51 | 31 | 4.2 | 3.9 | 388 | 78/83 | 3.7 |
| SD | 0.1 | 4 | 3.2 | 1.1 | 0.8 | 22 | 0.9 | |
| 2. PYC | 2.7 | 52 | 30 | 3.9 | 4 | 378 | 98/122 | 3.8 |
| SD | 0.11 | 3.2 | 2.4 | 0.7 | 1 | 23 | 0.5 | |
| 3. TROX | 2.8 | 53 | 29 | 4.1 | 3.9 | 398 | 70/77 | 3.7 |
| SD | 0.2 | 2.4 | 3 | 0.8 | 0.3 | 18 | 0.6 | |
| 4. D-E | 2.82 | 52 | 29 | 4.2 | 4 | 382 | 65/71 | 3.6 |
| SD | 0.1 | 2.2 | 2.1 | 0.3 | 0.7 | 31 | 1 | |
| 5. ANX | 2.8 | 51 | 28 | 4.1 | 3.8 | 379 | 67/73 | 3.7 |
| SD | 0.11 | 2.1 | 2 | 0.8 | 0.9 | 24 | 1.1 | |
| 6. MYRT | 2.76 | 52 | 30 | 4.0 | 3.9 | 388 | 70/77 | 3.5 |
| SD | 0.1 | 2.6 | 2.5 | 0.7 | 0.8 | 12 | 1 | |
| 7. FLEB | 2,82 | 53 | 29 | 3.9 | 3.7 | 378 | 68/74 | 3.6 |
| SD | 0.2 | 3.2 | 3 | 0.8 | 0.7 | 22 | 0.8 | |
| 8. ESC | 2.78 | 52 | 31 | 4.1 | 4 | 382 | 55/64 | 3.7 |
| SD | 0.13 | 2.6 | 2.2 | 1 | 0.8 | 26 | 0.9 | |
| 9. VE-PY | 2.76 | 52 | 29 | 4.06 | 4.1 | 375 | 155/173 | 3.6 |
| SD | 0.1 | 3 | 2.5 | 1.1 | 0.4 | 22 | 0.5 | |
| 10. ECOM | 2.81 | 51 | 30 | 4.1 | 3.9 | 387 | 198/237 | 3.8 |
| SD | 0.2 | 2.1 | 2 | 0.5 | 0.7 | 21 | 1.1 | |
Abbreviation: VE-PY, Pycnogenol + Venoruton association.
Note: All patients were treated/supplemented according to suggested dosages for at least 12 months.
Laser Doppler flux at the internal perimalleolar region; flux expressed in flux units; PO 2 and PCO 2 : in mmHg.
The clinical picture included symptomatic varicose veins and CVI.
This study lasted at least four seasons for all patients. These are the initial, inclusional values.
Comparative standard management with elastic compression stockings is also shown.
Measurements include SD (however, all these items should be considered nonparametric: intra-individual variation in measurements is < 8%).